3M Drug Delivery Systems undertakes new phase with Panacea Pharmaceuticals

3M Drug Delivery Systems will continue its collaboration with Panacea Pharmaceuticals Inc., this time working on a new phase in its study of an investigational therapeutic cancer vaccine that would be delivered to the dermis via 3M's Hollow Microstructured Transdermal System (hMTS).
Though it is still in the investigational stages, pre-clinical studies have indicated that hMTS may yield better immune response than intramuscular dosing. Additionally, safety studies have proved them to be high in tolerability of the drug. 
The first patient from the Phase 1 clinical study received Panacea's innovative cancer vaccination.
The hMTS delivery method has various benefits in addition to the superior immune response, including reproducible intradermal delivery and the capability of delivering up to 2mL with various viscosities. 
"Panacea and 3M have had a great relationship and we're excited to continue working with them," Sylvia Perez, president and general manager of 3M Drug Delivery System, said. "Our hollow microneedles bring a new value proposition to their work with therapeutic cancer vaccines offering the convenience of the transdermal patch, paired with a coveted high-volume, reproducible delivery capability to the dermis."